NanoVibronix announces 1-for-10 reverse stock split effective August 11

TYLER, Texas - NanoVibronix, Inc. (NASDAQ:NAOV), a medical technology company specializing in non-invasive therapeutic devices with a market capitalization of $2.15 million and annual revenue of $2.66 million, announced Thursday it will implement a 1-for-10 reverse stock split of its common stock effective August 11, 2025. According to InvestingPro data, the company faces significant challenges with cash burn and debt management.

The company’s shares will continue trading on the Nasdaq Capital Market under the symbol "NAOV" but will begin trading on a split-adjusted basis when markets open on Tuesday, August 12, 2025.

Following the reverse split, NanoVibronix’s outstanding common shares will be reduced from approximately 7.97 million to 796,887 shares. The company stated that any fractional shares resulting from the split will be rounded up to the nearest whole number.

The reverse split was approved by stockholders at a special meeting held on July 17, 2025, which granted the board of directors discretion to implement a reverse split at a ratio between 1-for-2 and 1-for-50.

Stockholders holding shares through brokerage accounts will have their shares automatically adjusted to reflect the split, while those holding certificated shares are not required to exchange their existing stock certificates, according to the company’s press release statement.

NanoVibronix develops acoustic-based therapeutic technologies including PainShield and UroShield, which utilize surface acoustic wave technology, as well as the ENvue Navigation Platform, an FDA-cleared electromagnetic system for feeding tube placement.

The company did not specify the reason for implementing the reverse split in its announcement.

In other recent news, NanoVibronix, Inc. announced shareholder approval for a reverse stock split proposal, with the board authorized to implement a split ratio ranging from 1-for-2 to 1-for-50 within the next year. Additionally, the company secured $8 million in funding through the sale of convertible preferred stock, with the potential for more in the future. NanoVibronix also experienced a procedural delay when a special meeting was adjourned due to a lack of quorum, with the meeting rescheduled for July 17, 2025.

In another development, the company corrected a typographical error in its Series G Preferred Stock filing, adjusting the floor price from $1.02 to $1.91. Furthermore, NanoVibronix received a U.S. patent for its pediatric feeding tube guidance system, enhancing its medical technology portfolio. These recent developments highlight a period of significant corporate activity for NanoVibronix.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.